Effectiveness of Nigella sativa Oil in the Management of Rheumatoid Arthritis Patients: A Placebo Controlled Study
Phytotherapy Research, 05/04/2012
Gheita TA et al. – Supplementation with Nigella sativa during DMARD therapy in RA may be considered an affordable potential adjuvant biological therapy.
Data from 40 female RA patients diagnosed according to the 2010 ACR/EULAR were analysed and discussed.
The patients took two placebo (starch filled) capsules daily for 1month.
This was followed by a month of Nigella sativa oil capsules 500 mg twice/day.
The disease activity score (DAS–28) significantly decreased after receiving the Nigella sativa capsules (4.55 ± 0.82) compared with before and after placebo (4.98 ± 0.79 and 4.99 ± 0.72, respectively) (p = 0.017).
Similarly, the number of swollen joints and the duration of morning stiffness improved.
A marked improvement in the disease activity was shown by both the ACR20 and EULAR response criteria in 42.5% and 30% of the patients, respectively, after intake of Nigella.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.